Navera Investment Management Ltd. Sells 189,285 Shares of Thermo Fisher Scientific Inc. $TMO

by · The Markets Daily

Navera Investment Management Ltd. lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 28.5% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 475,608 shares of the medical research company’s stock after selling 189,285 shares during the period. Thermo Fisher Scientific accounts for about 4.4% of Navera Investment Management Ltd.’s holdings, making the stock its 12th biggest holding. Navera Investment Management Ltd.’s holdings in Thermo Fisher Scientific were worth $230,555,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Highline Wealth Partners LLC increased its holdings in Thermo Fisher Scientific by 126.9% during the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after purchasing an additional 33 shares in the last quarter. Capital A Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific by 825.0% during the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after buying an additional 66 shares in the last quarter. DiNuzzo Private Wealth Inc. lifted its stake in Thermo Fisher Scientific by 406.7% in the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 61 shares in the last quarter. HighMark Wealth Management LLC raised its holdings in shares of Thermo Fisher Scientific by 140.6% in the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 45 shares during the last quarter. Finally, Howard Hughes Medical Institute acquired a new position in Thermo Fisher Scientific during the second quarter worth $33,000. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

TMO has been the subject of a number of recent research reports. Redburn Partners set a $580.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, October 8th. KeyCorp upgraded Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price objective on the stock in a research note on Sunday, December 7th. Morgan Stanley boosted their target price on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Argus increased their price target on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average price target of $625.47.

Check Out Our Latest Report on TMO

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $619.16 on Friday. The firm’s fifty day moving average price is $586.34 and its two-hundred day moving average price is $524.54. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The company has a market cap of $232.62 billion, a P/E ratio of 35.77, a P/E/G ratio of 4.07 and a beta of 0.91. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $629.87.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same period in the prior year, the firm earned $5.28 EPS. The business’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Monday, December 15th were given a dividend of $0.43 per share. The ex-dividend date was Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

Thermo Fisher Scientific announced that its board has authorized a stock buyback program on Thursday, November 6th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to buy up to 2.4% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its stock is undervalued.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 7,250 shares of the firm’s stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $566.10, for a total transaction of $4,104,225.00. Following the transaction, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $64,400,668.20. This trade represents a 5.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michel Lagarde sold 22,046 shares of the business’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $563.56, for a total transaction of $12,424,243.76. Following the completion of the sale, the chief operating officer directly owned 84,117 shares of the company’s stock, valued at $47,404,976.52. This represents a 20.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 149,271 shares of company stock valued at $86,507,282. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).